phrykt

Gain Therapeutics, Inc. (GANX): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of GANX were reported in the last 12 months. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Gain Therapeutics

From the latest filings

Overall: more buying than selling. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns GANX

50 funds and institutions reported GANX shares worth $18.6M at the end of Q2 2026, about 22% of the company. The largest holder is Marshall Wace, LLP with 4.5%.

Funds and institutions (13F) 22%Everyone else 78%

10 largest owners, by share of the company

Marshall Wace, LLP4.5%
Cambridge Investment Research Advisors, Inc.2.7%
Potomac Capital Management, Inc.2.2%
Gsa Capital Partners LLP1.5%
Jones Financial Companies Lllp1.4%
DME Capital Management, LP1.3%
Vanguard Capital Management LLC1.1%
Geode Capital Management, LLC1.1%
BlackRock, Inc.0.6%
Vanguard Fiduciary Trust Co0.5%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Marshall Wace, LLP1.92M4.51%$3.9M+9%
Cambridge Investment Research Advisors, Inc.1.14M2.67%$2.3M+100%
Potomac Capital Management, Inc.946,4002.22%$1.9M-6%
Gsa Capital Partners LLP632,1311.48%$1.3M+102%
Jones Financial Companies Lllp608,5921.43%$1.1M-4%
DME Capital Management, LP566,1301.33%$1.1MNo change
Vanguard Capital Management LLC480,2691.13%$975K+20%
Geode Capital Management, LLC453,5011.06%$921K+1%
BlackRock, Inc.274,9570.64%$558K+22%
Vanguard Fiduciary Trust Co231,5340.54%$470K+1%
UBS Group AG215,0120.50%$436K-2%
Stratos Wealth Partners, LTD.200,0000.47%$406K+52%
Cresset Asset Management, LLC160,0000.38%$325KNo change
State Street Corp157,5370.37%$320KNo change
Citadel Advisors LLC154,5240.36%$314K+521%
Squarepoint Ops LLC136,3590.32%$277KNew
Morgan Stanley125,9720.30%$256K-10%
LPL Financial LLC117,2510.27%$238K+12%
Northern Trust Corp97,0130.23%$197K-15%
Susquehanna International Group, LLP78,2060.18%$159K-82%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No GANX insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

GANX short interest

Moderate short interest. 8.7% of GANX shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went up 23%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 3.89M GANX shares were sold short, 8.7% of the shares outstanding, up 21.9% from the report before. At the average daily volume of 701,695 shares, buying them all back would take about 5.5 trading days (days to cover).

Shares short, % of all shares

8.74%May 15Oct 309.47%

Days to cover

5.5May 15Oct 309.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20263.89M8.74%+22%701,6955.5
Oct 15, 20263.19M7.31%+4%490,2196.5
Sep 30, 20263.06M7.00%+6%515,3815.9
Sep 15, 20262.89M6.62%+3%325,1058.9
Aug 31, 20262.80M6.41%-5%365,4057.7
Aug 14, 20262.95M6.76%-8%604,0184.9
Jul 31, 20263.21M7.36%-10%483,1036.7
Jul 15, 20263.59M8.41%-1%886,1694.0
Jun 30, 20263.61M8.46%-7%2.00M1.8
Jun 15, 20263.87M9.07%+21%638,3256.1
May 29, 20263.20M7.50%+1%829,4263.9
May 15, 20263.16M7.41%-8%437,7657.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Gain Therapeutics company events

Gain Therapeutics filed 15 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 10, 2026.

  1. Nov 10, 2026ResultsReleased financial results. Filing
  2. Oct 28, 2026LeadershipGain Therapeutics, Inc. appointed Jeanette Weidner as its Vice President, Finance, with an effective date of October 28, 2026. Filing
  3. Oct 1, 2026AnnouncementGain Therapeutics, Inc. issued a press release announcing the presentation of a poster at the International Congress of Parkinson’s Disease and Movement Disorders, being held October 4-8, 2026, in Seoul, Korea. Filing
  4. Sep 28, 2026LeadershipGianluca Fuggetta, Senior Vice President of Finance, principal financial officer, and principal accounting officer of Gain Therapeutics, Inc., notified the Company of his intention to resign from his positions with the Company, with such resignation to be effective September 30, 2026, in order to… Filing
  5. Aug 11, 2026ResultsReleased financial results. Filing
  6. Jul 16, 2026AnnouncementGain Therapeutics, Inc. issued a press release and shareholder letter in which it announced, among other things, that its current cash and cash equivalents are anticipated to fund the Company’s operations into the second quarter of 2027, based on current operating plans, including the completion of… Filing
  7. Jun 29, 2026AnnouncementGain Therapeutics, Inc. announced that the U.S. Food and Drug Administration has authorized the Company’s Investigational New Drug application for GT-02287. Filing
  8. Jun 25, 2026VoteReported shareholder vote results. Filing
  9. May 26, 2026AnnouncementGain Therapeutics, Inc. disclosed interim clinical and biomarker data from Part 2 (the nine-month extension) of its Phase 1b open-label clinical study of GT-02287 in patients with Parkinson’s disease with or without a GBA1 mutation. Filing
  10. May 11, 2026ResultsReleased financial results. Filing
  11. Mar 26, 2026ResultsReleased financial results. Filing
  12. Mar 18, 2026AnnouncementWhich press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. Filing
  13. Feb 3, 2026AnnouncementShared information with investors. Filing
  14. Dec 18, 2025AnnouncementGain Therapeutics, Inc. issued a press release announcing results in exploratory endpoint from its Phase 1b clinical study of GT-02287 in people with Parkinson’s Disease. Filing
  15. Nov 28, 2025AnnouncementGain Therapeutics, Inc., filed a prospectus supplement with the U.S. Securities and Exchange Commission in connection with the Company’s “at the market offering” program for the offer and sale of up to $35.53 million of the Company’s common stock, par value $0.0001 per share, from time to time… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Gain Therapeutics financials

Famous investors that hold GANX

3 of the 50 well-known investors we track reported holding GANX in their latest 13F filing. The largest position is David Einhorn's, worth $979K.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
David Einhorn · Greenlight Capital (DME)Q3 2026566,130$979K0.0%No change
Jim Simons · Renaissance TechnologiesQ3 2026182,600$316K0.0%New
Ken Griffin · Citadel AdvisorsQ3 2026170,230$294K0.0%+10%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Gain Therapeutics, Inc. (GANX) stock

Who owns the most GANX stock?

The largest reported owner of Gain Therapeutics, Inc. (GANX) is Marshall Wace, LLP, with 4.5% of the company. In total, 50 funds and institutions reported holding GANX at the end of Q2 2026, together about 22% of the shares. See the largest owners.

Are GANX insiders buying or selling?

No GANX insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in GANX?

As of Oct 30, 2026, 3.89M GANX shares were sold short, 8.7% of the shares outstanding, up 21.9% from the report before. At the average daily volume of 701,695 shares, buying them all back would take about 5.5 trading days (days to cover). See the history.

Which famous investors hold GANX?

3 of the 50 well-known investors we track reported GANX in their latest 13F filing, including David Einhorn, Jim Simons, Ken Griffin. The largest position is worth $979K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.